Continuous subcutaneous insulin infusion (CSII)of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII

OBJECTIVE- Multiple daily injection (MDI) therapy of bolus insulin aspart and basal insulin glargine was compared with continuous subcutaneous insulin infusion (CSII) with aspart in type 1 diabetic patients previously treated with CSII. RESEARCH DESIGN AND METHODS - One hundred patients were enrolled in a randomized, multicenter, open-label, crossover study. After a 1-week run-in period with aspart CSII, 50 subjects were randomly assigned to MDI therapy (aspart immediately before each meal and glargine at bedtime) and 50 subjects continued CSII After 5 weeks of the first treatment, subjects crossed over to the alternate treatment for 5 weeks. During the last week of each treatment period, subjects wore a continuous glucose monitoring system for 48-72 h. RESULTS - Mean serum fructosamine levels were significantly lower after CSII therapy than after MDI therapy (343 +/- 47 vs. 355 +/- 50 mumol/l, respectively; P = 0.0001). Continuous glucose monitoring profiles over a 24-h time period showed that glucose exposure was 24 and 40% lower for CSII than MDI as measured by area under the curve (AUC) glucose greater than or equal to 80 mg/dl (1,270 +/- 742vs. 1,664 +/- 1,039 mg-h-dl(-1);P < 0.001) and AUC glucose greater than or equal to 140 mg/dl (464 +/- 452 vs. 777 +/- 746 mg-h-dl(-1), CSII vs. MDI, respectively; P < 0.001). Similar percentages of reported hypoglycemic episodes (CSII: 92%, MDI: 94%) and nocturnal (12:00 A.M. to 8:00 A.M.) hypoglycemic episodes (CSII: 73%, MDI: 72%). Major hypoglycemia was infrequent (CS11: two episodes, MDI: five episodes). CONCLUSIONS - In a trial of short durationm CSII therapy with insulin aspart resulted in lower glycemic exposure without increased risk of hypoglycemia, as compared with MDI with lower insulin aspart and glargine.